MBX Biosciences, Inc. MBX 深 沪
等待开盘 02-04 09:30:00 美东时间
39.22
+0.150
+0.38%
华盛通- 最 高40.5535
- 今 开39.20
- 成交量 273.90万股
- 最 低 37.75
- 昨 收 39.07
- 总市值 17.61亿
- 52周最高 44.89
- 市盈率 静 --
- 换手率 6.10%
- 52周最低 4.8069
- 委 比 7.57%
- 总股本 4490.23万
- 历史最高 44.89
- 量 比 5.00
- 振 幅 7.18%
- 历史最低 4.8069
- 每 手 1
- 风险率 9.20%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 希捷科技、德州仪器、HCA控股、通用汽车、波音、UPS等或多家机构上调目标价；布朗保险、康沃系统、Qorvo、联合健康等遭多家机构下调目标价
今日重点评级关注：Piper Sandler：维持Praxis Precision Medicine"超配"评级，目标价从450美元升至1200美元；Tigress Financial：维持Main International ETF"买入"评级，目标价从52美元升至66美元
01-29 11:06
Barclays Initiates Coverage On MBX Biosciences with Overweight Rating, Announces Price Target of $66
Barclays analyst Eliana Merle initiates coverage on MBX Biosciences (NASDAQ:MBX) with a Overweight rating and announces Price Target of $66.
01-28 22:45
美股大行评级 | 潜在上涨空间31.6%！巴克莱上调台积电目标价至450美元；第一地平线全国银行获5家机构上调目标价
今日重点评级关注：Guggenheim：维持MBX Biosciences"买入"评级，目标价从77美元升至88美元；摩根士丹利：维持DraftKings"超配"评级，目标价从50美元升至53美元
01-20 10:26
美股周涨跌榜 | 算力基建再提速！Galaxy Digital 涨超37%，获批电力容量翻番；创新药企IBRX大涨近137%
算力基建再提速！Galaxy Digital 周涨超37%，获批电力容量翻番；创新药企IBRX周涨近137%，在研创新药获批上市>>
01-17 10:31
Guggenheim Maintains Buy on MBX Biosciences, Raises Price Target to $88
Guggenheim analyst Seamus Fernandez maintains MBX Biosciences (NASDAQ:MBX) with a Buy and raises the price target from $77 to $88.
01-16 23:17
美股大行评级 | 瑞银上调美光科技目标价从300美元升至400美元；Freedom上调百度目标价从120美元升至160美元
今日重点评级关注：Needham：维持Vaxcyte"买入"评级，目标价从90美元升至110美元；Citizens: 维持LGI Homes"跑赢大市"评级，目标价从85美元升至95美元
01-08 18:33
Monte Rosa Therapeutics, Ventyx Biosciences, United Microelectronics And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were mixed, with the Dow Jones index falling around 0.2% on Wednesd...
01-07 23:03
美股大行评级 | 绩后评级出炉！联邦快递获多家大行上调目标价；耐克遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Pyxis Oncology"买入"评级，目标价从5美元升至7美元；Stifel：维持Oculis Holding"买入"评级，目标价从35美元升至40美元
2025-12-22 15:05
Earnings Scheduled For December 18, 2025
Companies Reporting Before The Bell • Birkenstock Holding (NYSE:BIRK) is expect...
2025-12-18 19:11
MBX Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13
MBX Biosciences, Inc. announced that its CEO, Kent Hawryluk, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 13, 2026. The company, focused on developing precision peptide therapies for endocrine and metabolic disorders, will discuss its pipeline, including treatments for chronic hypoparathyroidism, obesity, and post-bariatric hypoglycemia. The event will be webcast and available for replay on the com...
2025-12-15 13:00
